Stocks Health care MANE
NYSE · Health careVeradermics, Inc (MANE)
It posted a net loss of $70M. In fiscal 2025 capital spending exceeded operating cash flow by $71.6M. At June 30, 2026 it held $319.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Veradermics, Inc
- Net worth
- Veradermics, Inc has a market value (market cap) of $6.2B at the latest share price, and shareholders' equity of $813.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $71.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Veradermics, Inc's next report was expected around October 16, 2026 and is not on file with the SEC yet.
What Veradermics, Inc does
Veradermics, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker MANE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$70M | -$111.91 | -$71.6M |
| 2025 | n/a | -$26.5M | -$37.05 | -$23.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Veradermics, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- October 19, 2026
- October 13, 2026Passive stake (5% or more) SCHEDULE 13G
- August 21, 2026Activist stake changed SCHEDULE 13D/A
- August 14, 2026Activist stake changed SCHEDULE 13D/A
- August 11, 2026
- August 11, 2026
- August 7, 2026IPO registration S-1
- August 6, 2026Passive stake (5% or more) SCHEDULE 13G
- July 15, 2026
Insider trades
What the people running Veradermics, Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $92.4M worth of shares in the last 90 days and bought none on the open market. 13% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 1, 2026 | Hollander DavidChief R&D Officer | Received as pay | 9,650 | - |
| August 20, 2026 | Montanova Capital, LLCDirector | Exercised optionsindirect | 149,000 | - |
| August 20, 2026 | Montanova Capital, LLCDirector | Exercised optionsindirect | 151,000 | - |
| August 19, 2026 | Montanova Capital, LLCDirector | Soldindirect | 690,601 | $74.1M |
| August 19, 2026 | Montanova Capital, LLCDirector | Soldindirect | 59,399 | $6.4M |
| August 17, 2026 | Waldman Reid AlexanderChief Executive Officer, Director | Exercised options | 3,452 | $42.1K |
| August 17, 2026 | Waldman Reid AlexanderChief Executive Officer, Director | Soldpre-planned (10b5-1) | 11,527 | $1.2M |
| August 17, 2026 | Waldman Reid AlexanderChief Executive Officer, Director | Soldpre-planned (10b5-1) | 25,234 | $2.7M |
Who owns MANE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Patrick G. Enright13D, may seek influence with 5 related filers | 11.3% | May 5, 2026 |
| Montanova Capital, LLC13D, may seek influence with 3 related filers | 8.8% | August 21, 2026 |
| Fmr LLC13G, passive with 1 related filers | 7.6% | August 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 164 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Montanova Capital, LLC | 4,168,970 | 0 |
| Fmr LLC | 3,204,981 | +1,412,072 |
| SR One Capital Management, LP | 2,401,868 | 0 |
| Deep Track Capital, LP | 2,000,000 | +1,500,000 |
| Citadel Advisors LLC | 1,877,775 | +52,103 |
| Siren, L.L.C. | 1,655,374 | +150,000 |
| BlackRock, Inc. | 1,593,791 | +1,311,180 |
| Viking Global Investors LP | 1,561,494 | -129,061 |
| Jpmorgan Chase & Co | 1,165,584 | +189,418 |
| Aberdeen Group plc | 1,096,642 | +41,982 |
| D. E. Shaw & Co., Inc. | 1,013,643 | +879,424 |
| Vanguard Capital Management LLC | 869,212 | +169,567 |
| Maverick Capital Ltd | 789,980 | new |
| Jennison Associates LLC | 748,678 | +606,897 |
| Infinitum Asset Management, LLC | 731,149 | 0 |
| UBS Group AG | 670,727 | +323,652 |
| Marshall Wace, Llp | 585,560 | -69,041 |
| Adage Capital Partners GP, L.L.C. | 549,706 | -550,294 |
| State Street Corp | 544,369 | +469,969 |
| Geode Capital Management, LLC | 508,067 | +329,861 |
Insiders
9 insiders reported holding 5,623,506 shares in total, about $834.8M at the last price.
| Holder | Shares |
|---|---|
| Longitude Capital Partners V, LLC10% owner | 2,053,4742,053,474 held indirectly |
| Enright Patrick GDirector, 10% owner | 2,053,4742,053,474 held indirectly |
| Montanova Capital, LLCDirector | 612,033612,033 held indirectly |
| Coric VladDirector | 449,337319,398 held indirectly |
| Childs John WDirector | 194,117194,117 held indirectly |
| Waldman Reid AlexanderChief Executive Officer, Director | 170,824 |
| Durso Timothy AugustChief Technical Officer | 78,142 |
| Hollander DavidChief R&D Officer | 9,650 |
| Grant-Kels Jane M.Director | 2,455 |
Questions about MANE
What does Veradermics, Inc do?
Veradermics, Inc is a company in the Health care sector, listed on NYSE as MANE. Its shares trade on NYSE under the ticker MANE.
What is Veradermics, Inc's net worth?
Veradermics, Inc has a market value (market cap) of $6.2B at the latest share price, and shareholders' equity of $813.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Veradermics, Inc profitable?
No. In fiscal 2025 it reported a net loss of $70M.
When did Veradermics, Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from November 9, 2026.
When is Veradermics, Inc's next earnings report?
Veradermics, Inc's next report was expected around October 16, 2026 and is not on file with the SEC yet.
Similar companies
Compare MANE with
Follow MANE
Get an email when Veradermics, Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Veradermics, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.